| Abstrakt: |
CAMBRIDGE, Mass. , March 6, 2023 /PRNewswire/ -- Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced that company management of Aktis Oncology, including Matthew Roden, PhD, President and Chief Executive Officer, Shulamit Ron-Bigger, PhD, Chief Operating Officer, and Tyler Benedum, PhD, Senior Vice President and Head of CMC, will participate in one-on-one investor meetings at Cowen's 43rd Annual Healthcare Conference in Boston, MA, on Wednesday, March 8, 2023. [ABSTRACT FROM PUBLISHER] |
